July 2010 | Oncology & Biotech News

ASCO 2010: Opaxio Highly Active in Esophageal Cancer

August 14, 2010

A drug that delivers paclitaxel in a novel way has yielded favorable results in a phase II trial of patients with advanced esophageal cancer, prompting the company developing the drug to plan a phase III trial.